FORT WORTH, Texas--(BUSINESS WIRE)--Sept. 18, 2006--Alcon, Inc. (NYSE:ACL) announced today that one of its affiliates has signed a collaboration and license agreement with NovaCal Pharmaceuticals, Inc. (“NovaCal”) to research, develop and commercialize NovaCal’s novel Aganocide(TM) compounds to treat infections of the eye, ear and sinus. Alcon said it believes NovaCal’s Aganocide(TM) compounds have the potential to be important in the treatment of such infections because of their broad application to bacterial, viral and fungal infections.
